论文部分内容阅读
目的:研究耐多药肺结核合并糖尿病患者进行免疫药物胸腺肽、抗结核药物联合的临床价值.方法:择取2019年1月到2020年1月期间收治的80例耐多药肺结核合并糖尿病患者作为研究,按照随机数字表法的形式将患者分为实验组和参照组,每组40例,参照组行常规的抗结核药物治疗,实验组在参照组的基础上加行免疫药物胸腺肽治疗,比较2组痰菌转阴、病灶吸收情况、空洞闭合情况、治疗前后2组T淋巴细胞亚群的变化.结果:实验组痰菌转阴、病灶吸收情况、空洞闭合情况均高于参照组,组内具有统计学价值(P＜0.05);治疗前,2组T淋巴细胞亚群的变化无差异(p＜0.05);治疗后,实验组CD8+低于参照组,且实验组CD4+,CD4+/CD8+高于参照组,组间具有差异(P＜0.05).结论:耐多药肺结核合并糖尿病患者实施免疫药物胸腺肽联合抗结核药物治疗,可以提升患者的痰菌转阴,病灶吸收,空洞闭合,整体治疗效果显著.“,”Objective: To study the clinical value of the combination of immune drug thymosin and anti-tuberculosis drugs in patients with multi-drug resistant pulmonary tuberculosis complicated with diabetes. Methods: 80 patients with multi-drug resistant pulmonary tuberculosis complicated with diabetes admitted from January 2019 to January 2020 were selected as the study. The patients were randomly divided into experimental group and reference group, with 40 cases in each group. The reference group was treated with conventional anti-tuberculosis drugs, while the experimental group was treated with immune drug thymosin on the basis of the reference group. The sputum bacteria turned negative, lesion absorption, cavity closure and T lymphocyte subsets of the two groups before and after treatment were compared Results: The sputum bacteria turned negative, the absorption of lesions and the cavity closure in the experimental group were higher than those in the reference group, with statistical value in the group (P ＜ 0.05). Before treatment, there was no difference in T lymphocyte subsets between the two groups (P ＜ 0.05). After treatment, CD8+ in the experimental group was lower than that in the reference group, and CD4+, CD4+/CD8+ in the experimental group were higher than that in the reference group, with differences between groups (P＜0.05). Conclusion: The application of immune drug thymosin combined with antituberculosis drugs in patients with multi-drug resistant pulmonary tuberculosis complicated with diabetes can improve sputum negative, focus absorption and cavity closure, and the overall treatment effect is remarkable.